Manson Fok - Apr 21, 2023 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
Director
Signature
/s/ Staci Holquist, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Apr 21, 2023
Transactions value $
$7,500
Form type
4
Date filed
4/24/2023, 04:36 PM
Previous filing
Jan 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Award $7.5K +5.75K +5.48% $1.31 111K Apr 21, 2023 Direct F1, F2
holding ATNXQ Common Stock 33.9K Apr 21, 2023 By Avalon Biomedical (Management) Limited F2, F3, F4
holding ATNXQ Common Stock 5.36K Apr 21, 2023 By Avalon Polytom (HK) Limited F2, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 2.4K Apr 21, 2023 Common Stock 2.4K $91.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 1K Apr 21, 2023 Common Stock 1K $91.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 2K Apr 21, 2023 Common Stock 2K $91.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 2.4K Apr 21, 2023 Common Stock 2.4K $150.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 2.4K Apr 21, 2023 Common Stock 2.4K $180.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 1.35K Apr 21, 2023 Common Stock 1.35K $220.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 2.75K Apr 21, 2023 Common Stock 2.75K $180.00 By Avalon Biomedical (Management) Limited F3, F4, F6
holding ATNXQ Stock Option (Right to Buy) 750 Apr 21, 2023 Common Stock 750 $346.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 500 Apr 21, 2023 Common Stock 500 $263.40 Direct F6
holding ATNXQ Stock Option (Right to Buy) 500 Apr 21, 2023 Common Stock 500 $249.00 Direct F6, F7
holding ATNXQ Stock Option (Right to Buy) 313 Apr 21, 2023 Common Stock 313 $76.00 Direct F6
holding ATNXQ Stock Option (Right to Buy) 625 Apr 21, 2023 Common Stock 625 $9.14 Direct F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
F2 As of February 15, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-20, resulting in every 20 shares owned by the reporting person to be combined into one share of common stock.
F3 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Mason Fok, M.B., B.S. ("Dr. Fok"), together with his spouse, own all of the outstanding interests in Sino Glory Developments Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Fok serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F4 Dr. Fok disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Fok is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F5 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F6 This option was adjusted to reflect the reverse stock split that occurred on February 15, 2023.
F7 This option vests in four equal annual installments beginning on June 5, 2021.
F8 This option vests on June 28, 2023.